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Hepatitis C virus (HCV) infection is a global medical problem. The current standard of treatment consists of the combination of
peginterferon plus ribavirin. This regimen eradicates HCV in 55% of cases. The immune response to HCV is an important
determinant of disease evolution and can be influenced by various host factors. HLA class II may play an important role in
immune response against HCV. The objective of the present study was to determine the distribution of HLA class II (DRB1 and
DQB1) alleles, their association with chronic HCV infection and their response to interferon therapy. One hundred and two
unrelated white Brazilian patients with chronic HCV infection, 52 responders (45 males and 7 females) and 50 non-responders
(43 males and 7 females) to antiviral treatment, were included in the study. Healthy Brazilian bone marrow donors of Caucasian
origin from the same geographic area constituted the control group (HLA-DRB1, N = 99 and HLA-DQB1, N = 222 individuals).
HLA class II genotyping was performed using a low-resolution DRB1, DQB1 sequence-specific primer amplification. There were
higher frequencies of HLA-DRB1*13 (26.5 vs 14.1%) and HLA-DQB1*02 (52.9 vs 38.7%) in patients compared with controls;
however, these were not significantly different after P correction (Pc = 0.39 and Pc = 0.082, respectively). There was no
significant difference between the phenotypic frequencies of HLA-DRB1 (17.3 vs 14.0%) and HLA-DQB1 alleles in responder
and non-responder HCV patients. The HLA-DRB1*07 allele was significantly more common in HCV patients (33.3 vs 12.1%)
than in controls (Pc = 0.0039), suggesting that the HLA-DRB1*07 allele is associated with chronic HCV infection.
Key words: HLA class II; HLA DR/DQ; HLA genotyping PCR; Hepatitis C virus; Chronic hepatitis C; Interferon treatment
Research supported by Fundo de Amparo ao Ensino e Pesquisa (FAEP), UNICAMP. Publication supported by FAPESP.
Received September 20, 2007. Accepted September 5, 2008
Introduction
Hepatitis C virus (HCV), first described in 1989, is now
recognized as one of the main causes of chronic liver
disease worldwide. HCV infection becomes chronic in the
majority of cases, with only 10-20% of those infected not
developing persistent viremia. The immune response to
HCV may be an important determinant of disease resolution
and can be influenced by a number of host factors. It is not
clear why many of these individuals remain asymptomatic,
without significant liver damage, while others develop se-
vere liver disease, progressing to cirrhosis and hepatocellu-
lar carcinoma, or why only some of those who are treated
respond to interferon (IFN) therapy (1). An association be-
tween major histocompatibility complex (MHC) alleles and
clinical outcome of viral infection has been reported in hepa-
titis B virus (2) and human immunodeficiency virus (HIV)
infection (3). Genetic association studies have strongly sug-
gested that the human leukocyte antigen (HLA) class II
restricted response may be important in the immunological
885
Braz J Med Biol Res 41(10) 2008
HLA class II in Brazilian patients with chronic HCV infection
www.bjournal.com.br
control of HCV disease outcome, although the implicated
genes differ (4-7). Patients carrying the DQB1*0301 (or
DRB1*1101), an allele with close linkage disequilibrium,
have been consistently found (6,7), particularly in a previous
large study (8), to have an increased chance of having
cleared the virus spontaneously and, also, a weaker asso-
ciation with clearance after IFN-α treatment. Other associa-
tions have also been reported; for example, a British and
French group reported an association of HLA-DRB1*1101
and HLA-DQB1*0301 with HCV clearance in Caucasian
populations, and there was no association of HLA antigens
with persistent HCV infection (5,9). In contrast, a German
study found an association of HLA-DRB1*0301 with chronic
HCV (10). In addition, a Japanese group reported associa-
tion of HLA-DRB1*0405 and HLA-DQB1*0401 with chronic
liver disease due to HCV, and an association of HLA-
DRB1*1101, HLA-DRB1*1302, and HLA-DQB1*0604 with
HCV carriers has been reported (11). A Thai study demon-
strated that HLA-DRB1*0301 and HLA-DQB1*0201 are as-
sociated with persistent HCV infection, whereas HLA-
DRB1*0701 and HLA-DQA1*0201 are associated with pro-
tection against HCV infection (12). In contrast, a Polish study
showed the HLA-DRB1*0701-DQA1*0201-DQB1*02 hap-
lotype to be associated with both chronic infection and
response to IFN-α (1). This inconsistency could be due to the
small size of some studies, ethnic differences, or HCV
genetic variability.
There has been little research in this field in Brazil,
although HCV infection occurs at a moderately high rate in
the population. A study with a highly admixed Brazilian
population (104 HCV-antibody-positive patients and 166
healthy controls) suggested an association of spontaneous
HCV clearance with HLA allele groups DRB*01 01 and
DQB*01 03 (13). However, no data were found in the litera-
ture correlating the association between Brazilian HCV pa-
tients and both HLA and response to IFN treatment.
We determined the distribution of HLA class II alleles in
patients with chronic hepatitis C using a low-resolution
PCR-sequence-specific primer (SSP) method to assess
whether MHC class II alleles were associated with HCV
infection and with their response to IFN therapy.
Subjects and Methods
Subjects
One hundred and two unrelated, Caucasian Brazilian
patients (88 males, 14 females; mean age 44.3 ± 11.4 years;
age range 23-72 years), living in Campinas, SP, Southeast
Brazil, undergoing IFN-α treatment for chronic HCV infection
followed by the Study Group of Hepatitis at the UNICAMP
University Medical School Hospital, were included in this
study. The present study was approved by the Faculty of
Medical Sciences Ethics Committee and all patients gave
their written informed consent. All patients were positive for
both HCV antibodies (enzyme immunoassay, 4th genera-
tion, Murex, South Africa) and serum HCV RNA (RT-PCR,
Cobas Amplicor HCV, version 2.0, Roche, USA) and were
negative for both hepatitis B virus and HIV. A liver biopsy
was indicated in patients with a persistent (>6 months)
elevation of alanine aminotransferase 1.5 times above the
upper normal limit, with positive reactions to HCV antibodies
and to HCV RNA testing in serum. Eighty-three patients
were submitted to biopsy; among these, 75 patients showed
histological evidence of chronic hepatitis C. The stage of
fibrosis was determined according to METAVIR score, which
varied from 0 to 4 (F0 = no fibrosis; F1 = portal fibrosis without
septa; F2 = portal fibrosis with few septa; F3 = septal fibrosis,
without cirrhosis; F4 = cirrhosis) (14). Other causes of chronic
liver disease that were not HCV were excluded.
In 98 patients, HCV genotyping was carried out by
reverse hybridization (InnoLipa, Innogenetics, Belgium).
After HCV genotyping, all patients were submitted to an
interferon therapy. Forty-six patients with genotype 1 and
4 patients considered as genotype not defined (mix), re-
ceived 1 year of standard therapy (IFN-α-2a or -2b plus
ribavirin), while 52 patients with genotype 3 received 6
months of antiviral therapy, according to treatment guide-
lines (15-17). Responder and non-responder patients were
included in this study, about one year after the end of
interferon therapy. Sustained virological responders were
defined as patients who presented clearance of serum
HCV-RNA at the end of treatment and 6 months thereafter
(responder patients). Using this criterium, 52 patients were
considered to be responders and 50 patients were classi-
fied as non-responders (Table 1).
Healthy unrelated Caucasian Brazilian bone marrow
donors from the same geographic area constituted the
control group (HLA class II DRB1: N = 99; 53 males, 46
females; mean age 34.3 ± 11.4 years; age range 25-47
years; HLA class II DQB1: N = 222; 136 males, 86 females;
mean age 35.4 ± 9.7 years; age range 27-46 years).
HLA class II genotyping
Genomic DNA was immediately isolated from fresh
peripheral blood cells using a commercial DNA isolation kit
(PuregeneTM Gentra Systems, USA), according to manu-
facturer instructions. HLA class II alleles were determined
using Micro SSPTM HLA DNA typing trays (One Lambda,
USA). HLA class II genotyping was performed using a low-
resolution DRB1, DQB1 SSP amplification, according to
manufacturer instructions, in all individuals evaluated in
this study (patients and controls).
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After PCR processing, the amplified DNA fragments
were separated by agarose gel electrophoresis and visual-
ized by staining with ethidium bromide and exposure to
ultraviolet light; the results were documented by Polaroid
photography. Interpretation of PCR-SSP results was based
on the presence or absence of a specific amplified DNA
fragment. Because amplification during the PCR may be
adversely affected by various factors (pipetting errors,
poor DNA quality, presence of inhibitors, etc.), an internal
control primer pair was included in every PCR product. The
control primer pair amplifies a conserved region of the
human ß-globin gene, which is present in all DNA samples
and is used to check the integrity of the PCR product.
Whenever there is a positive specific typing band amplifi-
cation of an HLA allele, the product of the internal control
primer pair may be weak or absent due to the differences
in concentration and melting temperatures between the
specific primer pairs and the internal control primer pair.
The amplified DNA fragments of the specific HLA primer
pairs are smaller than the product of the internal control
primer pair, but they are larger than the diffuse, unincorpo-
rated primer band. Thus, a positive reaction for a specific
HLA allele or allele group is visualized on the gel as an
amplified DNA fragment between the internal control prod-
uct band and the unincorporated primer band.
Statistical analysis
Frequency of alleles was compared between groups
by the χ2 test with either the Yates correction or the Fisher
exact test. For all tests, P ≤ 0.05 was considered to be
significant, and the significant P value was corrected (Pc;
Bonferroni’s correction) for the number of alleles detected
at each locus.
Results
Selected characteristics of the patient cohort are pre-
sented in Table 1. No differences between the two groups
in relation to age, gender and genotype were found, with
the exception that F1 was more frequent in sustained
responders (30 vs 4.6%; P < 0.05), and F3 more frequent
in non-responders (34.9 vs 7.5%; P < 0.05). As observed
among non-responder patients to IFN therapy, there were
23/43 (53.5%) with significant fibrosis (F3 and F4) com-
pared to 5/40 (12.5%) responder patients (P < 0.05).
Among responder patients to IFN therapy, there was no
significant fibrosis (F0-F2) in 35/40 (87.5%), while no sig-
nificant fibrosis was encountered in 20/43 (46.5%) of non-
responder patients (P < 0.05).
Among HLA-DRB1 alleles, the frequencies of HLA-
DRB1*13 and HLA-DRB1*07 (P = 0.0003, Pc = 0.003)
Table 1. Characteristics of patients with chronic hepatitis C virus
(HCV) infection and their response to IFN-α therapy according to
fibrosis grade (Metavir score) and HCV genotype.
Characteristics Sustained responders Non-responders
(N = 52) (N = 50)
Age (mean ± SD) 43.2 ± 11.4 44.1 ± 9.2
Gender (male/female) 45/7 43/7
Liver biopsy (N = 83)
F0 6/40 (15%) 2/43 (4.6%)
F1 12/40 (30%) 2/43 (4.6%)*
F2 17/40 (42.5%) 16/43 (37.3%)
F3 3/40 (7.5%) 15/43 (34.9%)*
F4 2/40 (5.0%) 8/43 (18.6%)
HCV genotype (N = 98)
1 19 (39.6%) 27 (54%)
3 29 (60.4%) 23 (46%)
Data are reported as number with percent within parentheses.
Percent was calculated on the number of subjects in the group.
Metavir score: F0 = no fibrosis; F1 = portal fibrosis without septa;
F2 = portal fibrosis with few septa; F3 = septal fibrosis without
cirrhosis; F4 = cirrhosis. *P ≤ 0.005 compared to sustained
responders (χ2 test with Yates’ correction).
Table 2. Distribution of human leukocyte antigen class II (HLA-
DRB1) phenotype frequencies in patients with chronic hepatitis
C virus (CHCV) infection and in healthy control subjects.
HLA-DRB1 Control CHCV patients OR
(N = 99) (N = 102) (95%CI)
1 24 (24.1%) 16 (15.7%) 0.58 (0.27–1.24)
15 14 (14.1%) 16 (15.7%) 1.13 (0.49–2.63)
16 3 (3%) 9 (8.8%) 3.1   (0.74–14.93)
3 18 (18.2%) 25 (24.5%) 1.46 (0.7–3.05)
4 15 (15.1%) 23 (22.5%) 1.63 (0.75–3.56)
11 26 (26.3%) 25 (24.5%) 0.91 (0.46–1.81)
12 4 (4%) 1 (1%) 0.24 (0.01–2.29)
13 14 (14.1%) 27 (26.5%) 2.19 (1.01–4.76)
14 8 (8.1%) 4 (3.9%) 0.46 (0.11–1.78)
7 12 (12.1%) 34 (33.3%)* 3.63 (1.66–8.05)
8 6 (6.1%) 7 (6.9%) 0.97 (0.15–6.19)
9 3 (3%) 3 (2.9%) 1.14 (0.33–4.01)
10 7 (7.1%) 3 (2.9%) 0.4   (0.08–1.78)
Data are reported as number with percent of total subjects in the
group within parentheses. Pc (Bonferroni’s correction) = P x 13
corresponding to the number of HLA allelic groups tested (13
DRB1). Pc < 0.004 compared to controls (Fisher exact test).
were significantly higher in the patients with HCV infection
than in the control group. However, after P correction
(Bonferroni’s correction), the frequency of the HLA-
DRB1*13 allele was not significantly higher in the patients
(Table 2).
Among HLA-DQB1 alleles, the frequency of the HLA-
DQB1*02 was also significantly higher (P < 0.05) in the
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HCV clearance and two HLA types (DQB1*03, DRB1*11)
while identifying a new association with DRB3*02. How-
ever, these associations were identified only among the
Caucasian patients and not among African American pa-
tients (21).
These data support a role for class II alleles in the
immune response to HCV and underscore the importance
of studying genetic association in an ethnically diverse
cohort.
The present study was specifically designed to deter-
mine association, if any, of host HLA class II genotype
profile of chronic HCV patients with a response of HLA-
hepatitis C to IFN therapy in a Brazilian population of
Caucasian origin. We detected higher frequencies of HLA-
DRB1*13 and HLA-DQB1*02 in HCV patients but after
Bonferroni’s correction the P values were not statistically
significant. The HLA-DRB1*07 allele was significantly more
frequent in chronic HCV patients than in controls after
applying Bonferroni’s correction. Our data for the HLA
DRB1*07 allele are similar to those reported in a Polish
study in which the HLA-DRB1*0701-DQA1*0201-DQB1*02
haplotype was associated with both chronic infection and
response to IFN-α (1). In another study of Irish women, a
significant reduction in the frequency of HLA-DQB1*0501
was identified in the presence of HLA-DRB1*0701 in indi-
viduals chronically infected with HCV (22). An association
between the alleles HLA-DRB1*0701 and HLA-DRB4*0101
with persistent infection was also detected in another
study of European patients (8). The HLA-DRB1*0701 al-
lele has been reported to be associated with persistent
infection by hepatitis B virus, but until the present study not
with hepatitis C (2). In another study, of a Thai population
(12), the HLA-DRB1*0701 and HLA-DQA1*0201 alleles
were significantly decreased in the HCV-infected individu-
als compared with the uninfected controls. It was sug-
gested that these alleles are associated with protection
against HCV infection. In a French study, higher frequen-
cies of HLA-DQB1*0301 and HLA-DRB1*1101 were re-
ported for patients with transient hepatitis than for those
with chronic hepatitis (9) and an Italian study found that the
haplotypes HLA-DRB1*1104, HLA-DQA1*0501, HLA-
DQB1*0301 were associated with low frequency of HCV
infections, whereas HLA-DQA1*0201-DQB1*0201 predis-
posed patients to chronic hepatitis (23). As may be ob-
served, important differences exist between the studies in
relation to the alleles of class II and their protective effects
and associations with persistent and chronic infection by
HCV. Our data and those for other countries cited here
support a role for class II alleles in the immune response to
HCV and underscore the importance of studying genetic
associations in the ethnically diverse cohorts.
Table 3. Distribution of human leukocyte antigen class II (HLA-
DQB1) phenotype frequencies in patients with chronic hepatitis
C virus (CHCV) infection and in healthy control subjects.
HLA-DQB1 Number of alleles (%)
Control CHCV patients OR
(N = 222) (N = 102) (95%CI)
2 86 (38.7%) 54 (52.9%)* 1.78 (1.08-2.94)
3 119 (53.6%) 52 (51%) 0.9   (0.55-1.48)
4 24 (10.8%) 6 (5.9%) 0.52 (0.18-1.39)
5 79 (35.6%) 36 (35.3%) 0.99 (0.59-1.66)
6 85 (38.3%) 39 (38.2%) 1.0   (0.59-1.66)
Data are reported as number with percent of total subjects in the
group within parentheses. Pc (Bonferroni’s correction) = P x 5
corresponding to the number of HLA allelic groups tested (5
DQB1). *P < 0.017 compared to controls (χ2 test with Yates’
correction), Pc > 0.05 compared to controls (χ2 test with Yates’
correction).
patients with HCV infection than in the control group.
However, this difference was not significant after P correc-
tion (Table 3). Also, there was no significant difference
between the phenotype frequencies of HLA-DRB1 and
HLA-DQB1 alleles in patients who were sustained re-
sponders and non-responders (P > 0.05). Analysis of the
relationship between response to IFN therapy and all
haplotypes in linkage disequilibrium indicated that there
were no statistically significant differences observed be-
tween the groups studied.
Discussion
HLA class II may play an important role in host immune
reactions against viral infection because it is a key protein
for antigen presentation by antigen-presenting cells to T-
helper cells. Since T-helper cells recognize peptides pre-
sented by HLA class II molecules, it is reasonable to
investigate HLA class II (DRB1 and DQB1) gene polymor-
phisms in patients with HCV infection (6,18,19). There is
also strong evidence (8,13) that class II genes are involved
in control of HCV, notably a protective effect of HLA-
DQB1*0301 (and/or DRB1*1101, which is in close linkage
disequilibrium). A study had observed that HLA-DQB1*0301
was weakly associated with viral clearance in combined
ethnic groups, but was strong in black subjects (20). In
white subjects, viral clearance was associated with
DRB1*0101 and its DQB1*0501 haplotype, whereas viral
persistence was associated with DRB1*0301 (6,9,20).
A recent study on Caucasian and African Americans
confirmed the previously reported associations between
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HCV persists in most infected individuals and is re-
sponsible for a wide spectrum of chronic liver lesions,
ranging from minimal inflammation to cirrhosis or hepato-
cellular carcinoma. Approximately 20% of infected pa-
tients successfully eliminate the virus (24) while the re-
mainder continues with chronic infection.
Treatment with IFN can improve the natural history of
chronic HCV. A number of factors predicting the response
to IFN therapy as genotype other than HCV genotype 1b,
lower levels of viremia, and the absence of cirrhosis have
been associated with more favorable responses (25,26).
Therefore, it is likely that inherited differences in genes
regulating immune reactivity may affect individual re-
sponses to its therapeutic use (27,28). HLA class II alleles,
although consistently associated with the expression of
HCV-related liver disease, have failed so far to show any
reproducible effect on IFN treatment response in inde-
pendent studies (8,29). An association of response to IFN
with HLA-DR 2 and DRB1*0404 has been reported in
Egyptian (30) and Canadian (31) patients, respectively,
but in both studies only the biochemical response was
evaluated based on the decrease of the alanine ami-
notransferase level in serum during therapy and not the
virological response (clearance of HCV-RNA in serum). A
Japanese study that considered virological response found
the DRB1*07 allele to be closely related to the complete
response, whereas DRB1*04 showed no response at all
(32). A Polish study showed the HLA-DRB1*0701-
DQA1*0201-DQB1*02 haplotype to be associated with
both chronic infection and response to IFN-α (1). In an-
other study of Taiwanese patients, the alleles HLA-A11,
HLA-B51, HLA-Cw15 and HLA-DRB1*15 were positively
correlated with a sustained response, whereas HLA-A24
was inversely associated with response to IFN-α. The
HLA-A11-HLA-DRB1*15 haplotype was strongly associ-
ated with a sustained response (33).
However, in the present study of Brazilian patients, we
did not detect any difference in the distribution of MHC
class II alleles between responder and non-responder
patients. In addition, responder patients had less fibrosis
than non-responder patients; thus, fibrosis may influence
the response to IFN directly.
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